News & Updates

New drug applications approved by US FDA as of 16 - 30 November 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Structural valve dysfunction (SVD) has occurred in nearly one in four young women with bioprosthetic heart valves (BPVs) at the first antenatal visit, and this may have harmful effects in pregnancy outcomes, reports a study. Specifically, SVD of left-sided BPVs is associated with high rates of adverse events (AEs).

Despite testing positive in unadjusted analyses, the impact of sleep apnoea and insomnia in pregnancy on infant outcomes appears nonsignificant, a recent study has found.

Injections of botulinum toxin A (BTA) in women with provoked vestibulodynia (PVD) does not appear to reduce dyspareunia or pain at tampon use when compared with placebo at 12 months’ follow-up, reports a recent study. However, women on BTA have attempted intercourse more often and have better sexual function than those on placebo.

New drug applications approved by US FDA as of 01 - 15 November 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Mood and anxiety symptoms experienced by women in the menopausal transition and in postmenopausal years may be effectively managed by nutritional interventions, according to a study.